Physician profile
Howard Fishman
NPI 1124156559
$2,966.52
in general payments reported to CMS, 2019-2025
21 companies · $591 in 2025
The $591 reported for 2025 was more than what 88% of Low Vision Rehabilitation providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $90.38 · 2021: $260 · 2022: $429 · 2023: $600 · 2024: $618 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,809.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $332.23 | 2023-2025 | Cequa |
| Biotissue Holdings INC. | $321.34 | 2022-2024 | |
| Bausch & Lomb Americas INC. | $255.49 | 2024-2025 | Infuse, Vyzulta |
| Amgen INC. | $239.87 | 2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $231.58 | 2024-2025 | Xdemvy |
| Coopervision INC. | $189.87 | 2019-2023 | Myday Contact Lens |
| Lumenis Be INC | $148.51 | 2022 | |
| Sight Sciences, INC. | $140.00 | 2023 | Tearcare System |
| Allergan, INC. | $137.63 | 2021 | |
| Dompe US, INC. | $124.99 | 2024 | Oxervate |
| Glaukos Corporation | $117.32 | 2019 | |
| Alcon Vision LLC | $115.28 | 2023 | Precision 1, Total30, Dailies Total1 |
| Visioneering Technologies, INC. | $92.55 | 2019 | |
| Genzyme Corporation | $77.18 | 2022 | |
| Abbvie INC. | $77.18 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $77.17 | 2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $73.32 | 2019 | |
| Kala Pharmaceuticals, INC. | $66.37 | 2021 | |
| Asd Specialty Healthcare, LLC | $62.15 | 2020 | |
| Maculogix, INC. | $58.26 | 2019 | |
| Optos, INC. | $28.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Fishman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.